Over 250 million people worldwide unaware they have diabetes, according to new research from the International Diabetes Federation (IDF)
New estimates from the IDF Diabetes Atlas highlight the growing diabetes threat,…
Study Finds Brain Training Also Helps Caregivers of Dementia Patients
SAN FRANCISCO, April 01, 2025 (GLOBE NEWSWIRE) -- While a particular brain…
European Commission Approves Pfizers RSV Vaccine ABRYSVO to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
ABRYSVO is the first and only RSV vaccine approved in the European…
Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults…
Honeywell Technology First to Proactively Manage Cyber Security Risk for Industrial Sites
- Honeywell's Cyber Security Risk Manager Gives Industrial Users Real-Time Visibility -…
Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first…
Dupixent (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
Five times more adults on Dupixent achieved sustained disease remission at 36…
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
Significantly more patients treated with Sotyktu achieved ACR and PASI response rates…
Education is a Pathway Toward Human Rights and Empowerment for Women and Girls Everywhere
International Women's Day Statement by Education Cannot Wait's Yasmine Sherif NEW YORK,…
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
– First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) – –…